<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03771781</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-BE-2018-EGLJ</org_study_id>
    <nct_id>NCT03771781</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.</brief_title>
  <official_title>A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study to Assess the Bioequivalence of Test Formulation With Reference Formulation in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions
      in Chinese Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-Center,Open-Label,Randomized,Single-Dose,Two-Period,Two-Sequence,Crossover Study to
      Assess the Bioequivalence of Test Formulation Empagliflozin Tablets with Reference
      Formulation Jardiance® in Chinese Healthy Adult Subjects under Fasting and Fed Conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">May 25, 2018</completion_date>
  <primary_completion_date type="Actual">May 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>0hours、0.67hours、1hours、1.5hours、2hours、2.5hours、3hours、4hours、6hours、8hours、12hours、24hours、36hours、48hours、72hours</time_frame>
    <description>Maximum observed plasma concentration following drug administration from the raw plasma concentration-time data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curves (AUC)</measure>
    <time_frame>0hours、0.67hours、1hours、1.5hours、2hours、2.5hours、3hours、4hours、6hours、8hours、12hours、24hours、36hours、48hours、72hours</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Empagliflozin Tablets</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin Tab 25 MG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Tablets</intervention_name>
    <description>Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.</description>
    <arm_group_label>Empagliflozin Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Tab 25 MG</intervention_name>
    <description>Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.</description>
    <arm_group_label>Empagliflozin Tab 25 MG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female, age 18 to 50 years, inclusive.

          2. The body weight of male is not less than 50kg, and female is not less than 45kg. All
             participants' body mass index (BMI) is between 19~26.

          3. Subjects are fully informed and voluntarily consent to participate in this study.

          4. Volunteers can communicate well with researchers and comply with the requirements of
             this study.

        Exclusion Criteria:

          1. Any with chronic or active gastrointestinal diseases such as esophageal diseases,
             gastritis, gastric ulcers, enteritis, active gastrointestinal bleeding or got any
             digestive tract surgery within three years.

          2. Any disease previously or currently suffering from circulatory system, endocrine
             system, nervous system, digestive system, respiratory system, hematology, immunology,
             psychiatry, and metabolic abnormalities, and which the researchers believe can
             interfere with the results of the test.

          3. Any history of allergy to drugs, food, or other substances.

          4. Dysphagia, difficulty in collecting blood or halo needle, history of dizziness.

          5. Those who have undergone surgery during the first four weeks of the trial or are
             scheduled to perform surgery during the study period.

          6. Those who has taken any drug (including vitamin products, Chinese herbs) within 14
             days before the study.

          7. Those who use any inhibits or induces hepatic metabolism within 30 days before the
             study.

          8. Those who participated in any clinical drug trial within 3 months prior to the trial.

          9. Those who donated or lose massive blood within 3 months before the study (&gt; 450 ml).

         10. Pregnant and lactating women.

         11. Male subjects (or their partners) or female subjects had unprotected sex or pregnancy
             plans within 2 weeks before screening and 6 months after the end of the trial, Those
             who are unwilling to use one or more non-drug contraceptive methods (e. G. Complete
             abstinence, contraceptive ring, partner ligation, etc.) during the study.

         12. Drug abusers or those who have used soft drugs for 3 months before the trial or who
             took hard drugs one year before the study.

         13. Those who has special requirements for diet and is unable to follow a uniform diet.

         14. Smokers or those who smoked more than 5 cigarettes a day 3 months before the study.

         15. An alcoholic or regular drinker for six months before the study, that is, a person who
             drinks more than 14 units of alcohol a week.

         16. People who drink excessive amounts of tea, coffee and/or caffeinated beverages (more
             than 8 cups, 1 cup =250 mL) per day or who do not agree to stop drinking tea, coffee
             and/or caffeinated beverages during the study period.

         17. Those who take drug or food which may affect the drug metabolism(including grapefruit
             or grapefruit products, dragon fruit, mango, pomelo, orange, yellow purine diet).Or
             the researchers think that there are other affect drug absorption, distribution,
             metabolism and excretion of diet.Or refuse to stop eating the diet during the study.

         18. Those with abnormal physical examination, electrocardiogram, laboratory examination,
             vital signs and test related examination with clinical significance .

         19. Those who has vital signs with clinical significance, positive urine screening test,
             positive alcohol breath test or positive female urine pregnancy.

         20. Those who has acute illness or concomitant medication occurred before participating in
             the study.

         21. Other reasons which,in the opinion of the medical investigator,would prevent the
             subject from participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Third Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 9, 2018</study_first_submitted>
  <study_first_submitted_qc>December 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

